Cytokinetics Earnings Estimate

CYTK
 Stock
  

USD 41.00  1.71  4.35%   

Many public companies, such as Cytokinetics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Cytokinetics' earnings estimates, investors can diagnose different trends across Cytokinetics' analyst sentiment over time as well as compare current estimates against different timeframes.
Cytokinetics is projected to generate -3.23 in earnings per share on the 31st of December 2021. Cytokinetics earnings estimates module stress-tests analyst consensus about projected Cytokinetics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Continue to Trending Equities.
  
Refresh
The current Gross Profit is estimated to decrease to about 59.3 M. The current Profit Margin is estimated to decrease to -3.3

Cytokinetics Earnings Estimation Breakdown

Calculation of earning per share of Cytokinetics is based on official Zacks consensus of 5 analysts regarding Cytokinetics future annual earnings. Given the historical accuracy of 69.0%, the future earnings per share of Cytokinetics is estimated to be -3.23 with the lowest and highest values of -3.44 and -2.91, respectively. Please note that this consensus of annual earnings estimates for Cytokinetics is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -3.11
-3.44
Lowest
Expected EPS -3.23
-2.91
Highest

Cytokinetics Earnings Projection Consensus

Suppose the current estimates of Cytokinetics' value are higher than the current market price of the Cytokinetics stock. In this case, investors may conclude that Cytokinetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cytokinetics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

5

69.0%

-3.11

-3.23

Cytokinetics Earnings History

Earnings estimate consensus by Cytokinetics analysts from Wall Street is used by the market to judge Cytokinetics' stock performance. The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Cytokinetics' upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods.

Cytokinetics Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(85.36 Million)

Share
The current Accumulated Retained Earnings Deficit is estimated to decrease to about (1.2 B). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (204.1 M) The current Issuance Purchase of Equity Shares is estimated to increase to about 345.2 M, while Weighted Average Shares is projected to decrease to under 65.4 M.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Cytokinetics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Cytokinetics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
35.6340.6245.61
Details
Intrinsic
Valuation
LowReal ValueHigh
40.0245.0150.00
Details
Naive
Forecast
LowNext ValueHigh
36.4741.4646.45
Details
11 Analysts
Consensus
LowTarget PriceHigh
40.0054.6775.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cytokinetics. Your research has to be compared to or analyzed against Cytokinetics' peers to derive any actionable benefits. When done correctly, Cytokinetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Cytokinetics.
Note that many institutional investors and large investment bankers can move markets due to the volume of Cytokinetics assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Cytokinetics. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Cytokinetics stock price in the short term.

Cytokinetics Earnings per Share Projection vs Actual

Actual Earning per Share of Cytokinetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cytokinetics predict the company's earnings will be in the future. The higher the earnings per share of Cytokinetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Cytokinetics Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Cytokinetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cytokinetics should always be considered in relation to other companies to make a more educated investment decision.

Cytokinetics Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Cytokinetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-04
2022-03-31-0.94-1.05-0.1111 
2022-02-24
2021-12-31-0.84-0.360.4857 
2021-11-03
2021-09-30-0.7625-0.95-0.187524 
2021-08-05
2021-06-30-0.6633-0.86-0.196729 
2021-05-06
2021-03-31-0.61-0.66-0.05
2021-02-25
2020-12-31-0.4933-0.62-0.126725 
2020-11-04
2020-09-30-0.565-0.050.51591 
2020-08-06
2020-06-30-0.5867-0.68-0.093315 
2020-05-06
2020-03-31-0.512-0.66-0.14828 
2020-03-03
2019-12-31-0.476-0.52-0.044
2019-10-31
2019-09-30-0.492-0.5-0.008
2019-08-08
2019-06-30-0.496-0.56-0.06412 
2019-05-09
2019-03-31-0.47-0.54-0.0714 
2019-02-21
2018-12-31-0.518-0.480.038
2018-11-01
2018-09-30-0.518-0.40.11822 
2018-07-26
2018-06-30-0.508-0.51-0.002
2018-04-26
2018-03-31-0.58-0.560.02
2018-02-15
2017-12-31-0.74-0.75-0.01
2017-10-26
2017-09-30-0.6243-0.60.0243
2017-08-02
2017-06-30-0.616-0.60.016
2017-04-27
2017-03-31-0.62-0.620
2017-02-16
2016-12-310.210.16-0.0523 
2016-10-27
2016-09-30-0.29330.741.0333352 
2016-07-28
2016-06-30-0.378-0.290.08823 
2016-04-28
2016-03-31-0.344-0.310.034
2016-02-16
2015-12-31-0.3217-0.240.081725 
2015-10-29
2015-09-30-0.3-0.230.0723 
2015-07-29
2015-06-30-0.23-0.27-0.0417 
2015-04-30
2015-03-31-0.12-0.23-0.1191 
2015-02-12
2014-12-31-0.170.230.4235 
2014-10-30
2014-09-30-0.24-0.160.0833 
2014-07-30
2014-06-30-0.32-0.230.0928 
2014-05-06
2014-03-31-0.34-0.270.0720 
2014-02-06
2013-12-31-0.080.210.29362 
2013-10-30
2013-09-30-0.1-0.43-0.33330 
2013-07-31
2013-06-30-0.54-0.58-0.04
2013-04-30
2013-03-31-0.55-0.540.01
2013-02-05
2012-12-31-0.61-0.420.1931 
2012-10-30
2012-09-30-0.63-0.420.2133 
2012-07-31
2012-06-30-0.76-0.78-0.02
2012-04-26
2012-03-31-0.86-0.780.08
2012-02-02
2011-12-31-1.06-0.960.1
2011-10-27
2011-09-30-1.17-0.90.2723 
2011-07-28
2011-06-30-0.64-1.38-0.74115 
2011-04-27
2011-03-31-1.14-1.080.06
2011-02-14
2010-12-31-1.33-1.020.3123 
2010-10-28
2010-09-30-1.25-1.140.11
2010-07-28
2010-06-30-1.21-1.26-0.05
2010-04-29
2010-03-31-1.19-1.2-0.01
2010-02-03
2009-12-31-1.32-1.260.06
2009-10-28
2009-09-30-1.29-0.840.4534 
2009-07-29
2009-06-303.025.942.9296 
2009-04-30
2009-03-31-1.25-1.26-0.01
2009-02-10
2008-12-31-2.32-1.32143 
2008-10-30
2008-09-30-2.2-1.980.2210 
2008-07-31
2008-06-30-1.99-1.860.13
2008-04-29
2008-03-31-1.9-1.680.2211 
2008-01-31
2007-12-31-2.43-1.620.8133 
2007-10-31
2007-09-30-2.35-1.440.9138 
2007-07-31
2007-06-30-2.17-1.620.5525 
2007-04-26
2007-03-31-2.41-1.50.9137 
2007-01-31
2006-12-31-3.49-2.461.0329 
2006-10-26
2006-09-30-3.01-2.460.5518 
2006-07-27
2006-06-30-2.89-2.220.6723 
2006-04-27
2006-03-31-2.91-2.160.7525 
2006-01-31
2005-12-31-2.83-2.280.5519 
2005-10-26
2005-09-30-2.44-2.10.3413 
2005-07-27
2005-06-30-2.74-2.220.5218 
2005-04-27
2005-03-31-2.68-2.220.4617 
2005-02-03
2004-12-31-2.36-2.52-0.16
2004-10-21
2004-09-30-2.88-2.160.7225 
2004-07-28
2004-06-30None-2.7825None
2004-06-16
2004-03-31None-1.3258None

About Cytokinetics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Cytokinetics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Cytokinetics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Cytokinetics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-1.2 B-1.2 B
Earning Before Interest and Taxes EBIT-198.9 M-204.1 M
Earnings per Basic Share(2.80) (3.02) 
Earnings per Diluted Share(2.80) (3.02) 
Price to Earnings Ratio(16.28) (16.71) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-196.6 M-201.8 M
Earnings before Tax-215.3 M-221 M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.5 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.